A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the number of ELN-guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations (<850 ng/mL) treated with nilotinib.
up to 2 years
United States: Food and Drug Administration
|Baylor Health Care System / Sammons Cancer Center Dept. of Sammons Cancer (2)||Dallas, Texas 75246|
|Cancer Center of the High Plains||Amarillo, Texas 79106|
|Comprehensive Cancer Centers of Nevada CCC of Nevada (1)||Las Vegas, Nevada 89109|